Clozapine plasma level monitoring for prediction of rehospitalization schizophrenic outpatients

Pharmacopsychiatry

Volumn 44, Issue 2, 2011, Pages 55-59

  Stieffenhofer, V ^a   Saglam, H ^a   Schmidtmann, I ^a   Silver, H ^b,c   Hiemke, C ^a   Konrad, A ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b SHA'AR MENASHE MENTAL HEALTH CENTER   (Israel)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; AMLODIPINE; ARIPIPRAZOLE; BUSPIRONE; CANDESARTAN; CLONAZEPAM; CLOZAPINE; DIAZEPAM; FLUVOXAMINE; GABAPENTIN; IODINE; LEVOMEPROMAZINE; LEVOTHYROXINE; LORAZEPAM; LORMETAZEPAM; MELPERONE; METFORMIN; METOPROLOL; OLANZAPINE; OMEPRAZOLE; PIRENZEPINE; PREGABALIN; QUETIAPINE; RAMIPRIL; REBOXETINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; UNINDEXED DRUG; VALPROIC ACID;

ARTICLE; BLOOD SAMPLING; CHRONIC PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXPLORATORY RESEARCH; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOSPITAL READMISSION; HUMAN; MALE; OUTPATIENT; PREDICTIVE VALUE; PRIORITY JOURNAL; RELAPSE; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY; SYMPTOM; TREATMENT DURATION;

ANTIPSYCHOTIC AGENTS; CLOZAPINE; DRUG MONITORING; FEMALE; HOSPITALIZATION; HUMANS; MALE; OUTPATIENTS; PATIENT READMISSION; RECURRENCE; SCHIZOPHRENIA; TIME FACTORS;

EID: 79953045899     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0030-1267178     Document Type: Article

References (22)

1. American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. Am J Psychiatry 1997 154 suppl 4 1-63
2. Baumann P, Hiemke C, Ulrich S et al,. Arbeitsgemeinschaft fur Neuropsychopharmakologie und Pharmakopsychiatrie. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 2004 37 243-265 (Pubitemid 39587052)
3. Beasley CM Jr, Stauffer VL, Liu-Seifert H et al,. All-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics: an integrated analysis. J Clin Psychopharmacol 2007 27 252-258
4. Davis JM. Overview: maintenance therapy in psychiatry, I: schizophrenia. Am J Psychiatry 1975 132 1237-1245
5. Diaz FJ, de Leon J, Josiassen RC et al,. Plasma clozapine concentration coefficients of variation in a long-term study. Schizophr Res 2005 72 131-135 (Pubitemid 39550984)
6. Dossenbach M, Arango-Davila C, Ibarra HS et al,. Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) Study. J Clin Psychiatry 2005 66 1021-1030 (Pubitemid 41191795)
7. Freeman DJ, Oyewumi LK. Will routine therapeutic drug monitoring have a place in clozapine therapy? Clin Pharmacokinet 1997 32 93-100 (Pubitemid 27104409)
8. Gaertner I, Gaertner HG, Vonthein R et al,. Therapeutic drug monitoring of clozapine in relapse prevention: a five-year prospective study. J Clin Psychopharmacol 2001 21 305-310 (Pubitemid 32452936)
9. Gilbert PL, Harris MJ, McAdams LA et al,. Neuroleptic withdrawal in schizophrenic patients: a review of the literature. Arch Gen Psychiatry 1995 52 173-188
10. Hiemke CH, Dragicevic A, Gründer G et al,. Therapeutic monitoring of new antipsychotic drugs. Ther Drug Monit 2004 26 156-160 (Pubitemid 38501210)
11. Hogarty GE, Schooler NR, Ulrich R et al,. Fluphenazine and social therapy in the aftercare of schizophrenic patients: relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Arch Gen Psychiatry 1979 36 1283-1294 (Pubitemid 11145664)
12. Hogarty GE, Ulrich RF. The limitations of antipsychotic medication on schizophrenia relapse and adjustment and the contributions of psychosocial treatment. J Psychiatr Res 1998 32 243-250 (Pubitemid 28408287)
13. Kurz M, Hummer M, Kemmler G et al,. Long-term pharmacokinetics of clozapine. Br J Psychiatry 1998 173 341-344 (Pubitemid 28454822)
14. Liebermann JA, Stroup TS, MacEvoy JP et al,. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005 353 1209-1223
15. Liu HC, Chang WH, Wei FC et al,. Monitoring of plasma clozapine levels and its metabolites in refractory schizophrenic patients. Ther Drug Monit 1996 18 200-207
16. Ng W, Uchida H, Ismail Z et al,. Clozapine exposure and the impact of smoking and gender: a population pharmacokinetic study. Ther Drug Monit 2009 31 360-366
17. Palego L, Biondi L, Giannaccini G et al,. Clozapine, norclozapine plasma levels, their sum and ratio in 50 psychotic patients: influence of patient-related variables. Prog Neuropsychopharmacol Biol Psychiatry 2002 26 473-480 (Pubitemid 34252940)
18. Rostami-Hodjegan A, Amin AM, Spencer EP et al,. Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J Clin Psychopharmacol 2004 24 70-78 (Pubitemid 38134168)
19. Sachse J, Köller J, Härtter S et al,. Automated analysis of quetiapine and other antipsychotic drugs in human blood by high performance-liquid chromatography with column-switching and spectrophotometric detection. J Chromatogr B Analyt Technol Biomed Life Sci 2006 830 342-348 (Pubitemid 43075471)
20. Stroup TS, McEvoy JP, Swartz MS et al,. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull 2003 29 15-31 (Pubitemid 36871054)
21. Ulrich S, Baumann B, Wolf R et al,. Therapeutic drug monitoring of clozapine and relapse - a retrospective study of routine clinical data. Int J Clin Pharmacol Ther 2003 41 3-13 (Pubitemid 36097874)
22. Xiang YQ, Zhang ZY, Weng JZ et al,. Serum concentrations of clozapine and norclozapine in the prediction of relapse of patients with schizophrenia. Schizophr Res 2006 83 201-210